167 related articles for article (PubMed ID: 36960201)
1. Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome.
Chen Y; Niu T; Chen T; Wu Y; Zou D; Shi C; Wu Y; Zhang Z; Wu N; Zhang Y; Yan X; Sheng L; Lv D; Ouyang G; Chen X; Mu Q
Front Nutr; 2023; 10():1125768. PubMed ID: 36960201
[TBL] [Abstract][Full Text] [Related]
2. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
3. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Papageorgiou SG; Kotsianidis I; Bouchla A; Symeonidis A; Galanopoulos A; Viniou NA; Hatzimichael E; Vassilakopoulos TP; Gogos D; Megalakaki A; Zikos P; Diamantopoulos P; Kourakli A; Giannoulia P; Papoutselis M; Poulakidas E; Arapaki M; Vardi A; Anagnostopoulos A; Mparmparousi D; Papaioannou M; Bouronikou E; Dimou M; Papadaki H; Panayiotidis P; Pappa V
Ther Adv Hematol; 2020; 11():2040620720966121. PubMed ID: 33343854
[TBL] [Abstract][Full Text] [Related]
4. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
Sabile JMG; Kaempf A; Tomic K; Manu GP; Swords R; Migdady Y
Leuk Lymphoma; 2023 Oct; 64(10):1689-1694. PubMed ID: 37440338
[TBL] [Abstract][Full Text] [Related]
5. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
6. [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].
Lu CQ; Hou C; Wang P; Zhang LW; Fan Y; Wu DP; Xu Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):247-254. PubMed ID: 35405784
[No Abstract] [Full Text] [Related]
7. Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes.
Shi C; Gong S; Wu A; Yang S; Zou D; Zhang Y; Wu N; Ma C; Shi S; Chen Y; Wu Y; Zheng X; Huang Z; Ding J; Ouyang G; Mu Q
BMC Cancer; 2022 Jan; 22(1):127. PubMed ID: 35100989
[TBL] [Abstract][Full Text] [Related]
8. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
Aguirre LE; Al Ali N; Sallman DA; Ball S; Jain AG; Chan O; Tinsley-Vance SM; Kuykendall A; Sweet K; Lancet JE; Padron E; Komrokji RS
Leukemia; 2023 Jul; 37(7):1530-1539. PubMed ID: 37147425
[TBL] [Abstract][Full Text] [Related]
9. Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.
Wu A; Gao P; Wu N; Shi C; Huang Z; Rong C; Sun Y; Sheng L; Ouyang G; Mu Q
BMC Cancer; 2021 May; 21(1):546. PubMed ID: 33985456
[TBL] [Abstract][Full Text] [Related]
10. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
11. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Value of Pretherapy Peripheral Blood Inflammatory Indices in Myelodysplastic Syndromes.
Shi C; Gong S; Niu T; Li T; Wu A; Zheng X; Yang S; Ouyang G; Mu Q
Front Oncol; 2022; 12():877981. PubMed ID: 35558519
[TBL] [Abstract][Full Text] [Related]
13. Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome.
Wang YH; Lin CC; Yao CY; Hsu CL; Tsai CH; Hou HA; Chou WC; Tien HF
Br J Haematol; 2022 Jan; 196(1):156-168. PubMed ID: 34536013
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome.
Ma J; Gu Y; Wei Y; Wang X; Wang P; Song C; Ge Z
Blood Sci; 2023 Jul; 5(3):187-195. PubMed ID: 37546714
[TBL] [Abstract][Full Text] [Related]
16. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients.
Wang YH; Lin CC; Yao CY; Hsu CL; Hou HA; Tsai CH; Chou WC; Tien HF
Blood Adv; 2020 Feb; 4(4):644-654. PubMed ID: 32078680
[TBL] [Abstract][Full Text] [Related]
17. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
[TBL] [Abstract][Full Text] [Related]
18. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
19. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
20. Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome.
Shi C; Gong S; Wu A; Niu T; Wu N; Zhang Y; Ouyang G; Mu Q
Cancer Manag Res; 2022; 14():1857-1865. PubMed ID: 35693118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]